In a landmark pilot study published in 2025 in BMC Cancer, researchers from India have investigated the prognostic value of lipid-based insulin resistance biomarkers in treatment-naïve CRC patients, examining how these markers correlate with metastatic status and other clinical parameters. The study enrolled 87 patients from four tertiary care hospitals, stratified into metastatic (n = 24) and non-metastatic (n = 63) groups. Comprehensive clinical assessments included TNM cancer staging, performance measures such as ECOG-Performance Status and Karnofsky Performance Scale, serum carcinoembryonic antigen (CEA) levels, and detailed lipid profiles encompassing LDL, HDL, and triglyceride indices.

The cornerstone of this research lies in elucidating the relationship between specific insulin resistance biomarkers and the propensity for CRC metastasis. Notably, the study focused on lipid ratios, such as the low-density lipoprotein to high-density lipoprotein ratio (LHR) and triglyceride-glucose index (TyG), as potential predictive indicators. Statistical analyses—ranging from Fisher’s exact tests to advanced regression models and receiver operating characteristic (ROC) curves—were employed to contextualize the diagnostic power of these markers within clinical data. Importantly, the binary logistic regression pinpointed LHR as a singularly strong predictor of metastatic disease, with increases in LHR corresponding to nearly a 20% heightened risk of metastasis.

These findings signify a breakthrough in understanding the metabolic underpinnings influencing tumor dissemination. The LHR demonstrated superb diagnostic metrics, achieving an area under the curve (AUC) of 0.867, alongside a sensitivity of 83.3% and specificity of 74.6%. Such performance metrics illustrate its potential utility as a non-invasive biomarker, potentially enabling clinicians to identify high-risk CRC patients at diagnosis, before metastasis becomes radiologically or clinically apparent. This advantage could revolutionize stratification strategies, allowing for tailored interventions predicated upon metabolic risk profiling.

Further insights from the study revealed that LHR’s predictive power was not an isolated phenomenon but was intricately associated with established clinical parameters including TNM stage, ECOG-PS, and serum CEA levels. The moderate positive correlations found via Spearman analysis emphasize the complex interdependence between lipid metabolism, tumor biology, and systemic disease status. These associations bolster the hypothesis that metabolic disruptions intrinsic to insulin resistance may facilitate or reflect mechanisms driving metastasis, such as altered cellular energetics, inflammatory cascades, and microvascular remodeling.

Crucially, these results emerge from a population of treatment-naïve patients, underscoring the biomarker’s capability to predict metastatic risk devoid of confounding effects from prior chemotherapy, radiotherapy, or surgical interventions. This clean clinical baseline enhances the reliability of the findings and suggests that the pathways connecting insulin resistance and metastasis are entrenched early in the disease course, possibly reflecting host metabolic milieu as much as tumor-intrinsic factors.

The study’s authors acknowledge the necessity of confirming these promising findings in larger, multi-centric cohorts with diverse ethnic and genetic backgrounds. While the pilot data strongly indicate LHR as a harbinger of metastatic progression, external validation will be pivotal before clinical integration. Furthermore, mechanistic studies exploring how lipid metabolism and insulin resistance drive metastasis at molecular and cellular levels would complement these epidemiological findings, potentially unveiling novel therapeutic targets.

From a clinical perspective, the incorporation of LHR into routine diagnostic algorithms could complement conventional staging approaches, such as imaging and histopathology, by adding a metabolic dimension to risk assessment. This stratification could identify patients who might benefit from intensified surveillance or early systemic therapies aimed at intercepting metastatic spread. Additionally, LHR is derived from commonly measured lipid panels, making it a cost-effective and easily implementable biomarker in diverse healthcare settings, including resource-limited environments where advanced molecular diagnostics are not readily available.

Insulin resistance’s intricate link with cancer biology encompasses various pathways, including hyperinsulinemia-induced cellular proliferation, dysregulated adipokine signaling, and chronic low-grade inflammation. The findings from this study reinforce the concept that metabolic syndrome components, such as dyslipidemia, are not merely comorbid risk factors but active participants in the neoplastic process, particularly in tumor aggressiveness and metastatic potential.

Importantly, the differentiation between LHR and other IR markers such as the TyG index highlights the nuanced landscape of metabolic biomarkers. While TyG did not show a significant correlation with either metastasis or CEA levels, LHR stood out as a robust and independent predictor. This specificity suggests that the balance between LDL and HDL cholesterol might be particularly reflective of biological processes pertinent to CRC progression, like oxidative stress and endothelial dysfunction.

The integration of IR biomarkers with traditional oncological parameters also opens new avenues for comprehensive prognostic models. The study’s multiple linear regression analysis underscores the combined predictive value of TNM staging, performance status scores, and LHR, suggesting that multifactorial models incorporating metabolic parameters could enhance prognostic precision beyond conventional staging alone.

Looking forward, such research may catalyze a paradigm shift in oncology towards metabolically informed cancer management. Interventions targeting insulin resistance, through lifestyle modifications or pharmacologic agents like metformin and statins, might gain prominence not only for metabolic health but also as adjunctive measures in cancer therapy aimed at reducing metastatic risk.

In summary, this pioneering study elucidates the pivotal role of lipid-based insulin resistance biomarkers, especially the LDL/HDL ratio, as powerful predictors of metastatic prognosis in treatment-naïve colorectal cancer patients. The findings herald a new frontier where metabolic profiling intersects with oncological diagnostics, offering hope for earlier detection, personalized treatment strategies, and ultimately improved survival in CRC.

Subject of Research: Association of insulin resistance biomarkers with metastatic prognosis in treatment-naïve colorectal cancer patients.

Article Title: Association between insulin resistance biomarkers and metastatic prognosis in treatment-naïve colorectal cancer patients: a pilot study

Article References: Narayanan, M.P., Sehrawat, A., Goyal, B. et al. Association between insulin resistance biomarkers and metastatic prognosis in treatment-naïve colorectal cancer patients: a pilot study. BMC Cancer 25, 1711 (2025). https://doi.org/10.1186/s12885-025-14669-w

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-14669-w (05 November 2025)

Gastric cancer remains one of the deadliest cancers worldwide, often diagnosed at advanced stages with limited curative options. Patients presenting with a performance status of 2—a clinical measure indicating significant debilitation—represent a particularly vulnerable cohort. Traditionally, their impaired health has constrained treatment choices, excluding them from intensive chemotherapy regimens that may exacerbate their frailty. Consequently, there has been a compelling need to explore regimens that can balance efficacy with tolerability in this delicate patient population.

The APICAL-GC trial harnesses the synergistic potential of anlotinib, an oral multi-targeted tyrosine kinase inhibitor known to impede tumor angiogenesis and proliferation, with toripalimab, a programmed cell death-1 (PD-1) immune checkpoint inhibitor designed to unleash the host’s anti-tumor immunity. By integrating these two modalities, the trial aims to exploit concurrent anti-angiogenic and immunomodulatory mechanisms. This dual-pronged approach could break the tumor’s protective microenvironment, facilitating a robust immune response against cancer cells.

Liu and colleagues executed the APICAL-GC trial meticulously, enrolling advanced gastric cancer patients characterized by performance status 2, who are seldom represented in clinical trials due to their fragile condition. Over the course of the study, the investigational combination demonstrated not only a manageable safety profile but also significant clinical activity, invoking meaningful response rates and survival benefits that surpass existing standards of care in this subgroup.

Central to the therapeutic success observed is anlotinib’s ability to inhibit vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR), effectively stalling angiogenic signaling pathways pivotal for tumor nourishment and expansion. Coupled with toripalimab’s immune checkpoint blockade—which alleviates T-cell exhaustion—the combination fosters a hostile milieu for tumor cells that shifts the balance towards tumor regression.

The trial’s methodology incorporated rigorous baseline assessments, along with serial radiographic and biomarker evaluations, to parse out response dynamics and mechanisms underlying treatment efficacy. Notably, the intertwined pharmacodynamics of angiogenesis inhibition and immune activation appear to recalibrate the tumor microenvironment, increasing T-cell infiltration and reducing immunosuppressive elements such as regulatory T cells and myeloid-derived suppressor cells.

Importantly, despite the vulnerable patient cohort, the APICAL-GC trial reported manageable adverse effects. Common toxicities aligned with those expected from both agents, including hypertension, proteinuria, fatigue, and immune-related adverse events, yet they seldom necessitated treatment discontinuation. This tolerability is particularly encouraging for performance status 2 patients, where treatment-related morbidity often compels early cessation of therapy.

The findings have far-reaching implications beyond gastric cancer, signaling a potential paradigm shift in oncologic treatment where combination strategies transcend monotherapies’ limitations by leveraging complementary mechanisms. The trial underscores the importance of broadening eligibility criteria in clinical studies to include patients with poorer functional status, thus generating evidence to guide treatment in real-world settings.

The mechanistic rationale behind this combination extends to tumor immunoediting concepts—the process by which tumors evade immune surveillance. Anlotinib’s normalization of aberrant vasculature may enhance immune cell trafficking, thereby potentiating toripalimab’s checkpoint inhibition by increasing effector T-cell access to tumor niches previously barricaded by hypoxia and abnormal vessels.

Furthermore, emerging biomarker analyses from APICAL-GC hint at predictive signatures that could refine patient selection. Factors such as PD-L1 expression, tumor mutational burden, and angiogenic gene signatures might stratify responders, enabling a precision medicine framework to optimize benefit-risk profiles.

Given gastric cancer’s heterogeneity, future investigations could explore combining anlotinib and toripalimab with additional agents, such as chemotherapy or targeted therapies, to further amplify efficacy. However, the current trial’s design focusing on a monotherapy-sparing approach is pivotal, reducing the toxicity burden that traditionally limits treatment tolerability in frail patients.

From an immunological perspective, toripalimab reinvigorates exhausted cytotoxic T cells by disrupting PD-1/PD-L1 interactions, a well-established axis leading to immune evasion in multiple cancers. By reactivating these effectors, it induces durable tumor cell killing and immunological memory formation, which may underpin sustained clinical responses observed.

The APICAL-GC trial’s success also underscores advances in drug development optimizing oral therapies, affording ease of administration and improved quality of life—key considerations for patients with diminished performance status. The oral availability of anlotinib simplifies treatment logistics, contrasting with intravenous agents requiring frequent hospital visits.

Moreover, this study exemplifies the benefits of integrating multidisciplinary management, encompassing oncology, immunology, molecular biology, and pharmacology, to dissect complex disease dynamics and therapeutic impacts accurately. Such comprehensive approaches underpin the translational science that bridges bench discoveries with bedside applications.

Looking forward, the researchers advocate for larger randomized phase III trials to validate these findings and explore long-term outcomes, including overall survival and quality of life metrics. Additionally, post-marketing surveillance will be vital to monitor rare adverse effects and real-world effectiveness across diverse populations.

In summary, the APICAL-GC phase II trial heralds a new horizon in treating advanced gastric cancer patients with performance status 2 by deftly combining anti-angiogenesis and immunotherapy. This combination therapy not only extends hope to a historically underserved patient group but also reinforces the paradigm that multifaceted targeting of the tumor and its microenvironment may overcome intrinsic resistance mechanisms, paving the way for enduring clinical benefits and improved patient outcomes.

Subject of Research: Advanced gastric cancer treatment, first-line therapy in patients with performance status 2

Article Title: Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial

Article References:
Liu, K., Qin, BD., Chen, SQ. et al. Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial. Nat Commun 16, 5069 (2025). https://doi.org/10.1038/s41467-025-60317-z

Image Credits: AI Generated